Details for Patent: 11,839,689
Which drugs does patent 11,839,689 protect, and when does it expire?
Patent 11,839,689 protects XTANDI and is included in one NDA.
This patent has forty-nine patent family members in twenty-nine countries.
Summary for Patent: 11,839,689
| Title: | Formulations of enzalutamide | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Abstract: | This disclosure provides formulations of enzalutamide and their use for treating hyperproliferative disorders. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Inventor(s): | Douglas Alan Lorenz, Sanjay Konagurthu, Randy J. Wald, Jason A. Everett, Sheila Matz, Yuuki Takaishi, Toshiro Sakai, Ryousuke Irie, Shinsuke Oba, Hiroyasu Toyota, Koji Nishimura, Atsushi Kanbayashi | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Assignee: | Astellas Pharma Inc , Medivation Prostate Therapeutics LLC | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Application Number: | US17/985,235 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 11,839,689 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Patent Claim Types: see list of patent claims | Composition; Compound; Dosage form; | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Patent landscape, scope, and claims: | # US Patent 11,839,689: Enzalutamide Solid-Dispersion Claims, Exclusivity, Litigation and Generic Risk US Patent 11,839,689 protects an enzalutamide formulation based on an amorphous solid dispersion with hydroxypropyl methylcellulose acetate succinate, commonly abbreviated HPMCAS. The broadest claim covers the composition itself. Dependent claims narrow protection to spray-dried dispersions, humidity-stable amorphous enzalutamide, 80-mg tablets, and tablets containing croscarmellose sodium and magnesium stearate. The patent is commercially relevant to Xtandi tablets because the approved product contains enzalutamide and formulation excipients consistent with the claimed technology. It does not claim the enzalutamide molecule, androgen-receptor inhibition generally, or every enzalutamide dosage form. Its value depends on whether the patent is listed in the FDA Orange Book, whether an accused generic uses the claimed HPMCAS dispersion, and whether the claims withstand validity challenges. What does US Patent 11,839,689 cover?US 11,839,689 covers a pharmaceutical composition containing a solid dispersion consisting essentially of amorphous enzalutamide and HPMCAS. The patent adds narrower protection for processing, storage stability, tablet strength, and excipient composition.
The patent therefore has a layered claim structure. Claim 1 provides the principal composition position. Claims 2 and 3 target the dispersion process and physical-state stability. Claims 4 through 7 target finished tablets and reduce the risk that a competitor can avoid infringement by modifying dosage-form or excipient details. How should the “consisting essentially of” language be interpreted?“Consisting essentially of” is narrower than “comprising” but broader than “consisting of.” It generally permits additional ingredients that do not materially affect the basic and novel characteristics of the claimed composition. For claim 1, the basic characteristics are likely:
An accused product could contain fillers, lubricants, disintegrants, glidants, coatings, or other conventional tablet ingredients without necessarily falling outside claim 1. The key issue would be whether the additional material materially changes the claimed solid-dispersion system. The language creates claim-construction risk for both sides. The patent owner may argue that conventional tablet excipients are permitted because they do not change the enzalutamide-HPMCAS dispersion. A generic applicant may argue that a different polymer, a crystalline or partially crystalline enzalutamide form, or a substantially different dispersion architecture falls outside the claim. What technical features are required for infringement?A product would generally need to satisfy each limitation of the asserted claim. Claim 1 infringementThe relevant questions are:
A formulation using a different polymer, such as polyvinylpyrrolidone, copovidone, or hypromellose, would present a noninfringement argument under the literal language of claim 1. The doctrine of equivalents could still be asserted, but prosecution history, claim amendments, and prior-art limitations would control its availability. Claim 2 infringementClaim 2 requires a spray-dried dispersion. A competitor using hot-melt extrusion, solvent evaporation, fluid-bed coating, or another manufacturing process may avoid literal infringement of claim 2 if the process does not produce a spray-dried dispersion. That alternative may still infringe claim 1 if the resulting product contains the claimed amorphous enzalutamide-HPMCAS solid dispersion. Claim 3 infringementClaim 3 adds a stability test: amorphous enzalutamide must remain amorphous after storage at 40°C and 75% relative humidity for one month. This limitation is useful against products designed to meet the composition and process elements but that differ in stability performance. The claim raises evidentiary issues. Parties would likely dispute:
Claims 4 through 7The tablet claims increase commercial relevance but reduce breadth. A generic product that uses the same dispersion in a capsule, suspension, or sachet may avoid claims 4 through 7 while remaining exposed to claim 1 or claim 2. Claim 7 is particularly narrow because it requires croscarmellose sodium at 6% to 10% of total tablet weight. A competitor using 5.5% or 10.5%, assuming accurate formulation and measurement, may have a literal noninfringement position. The patent owner could challenge small percentage changes under equivalents, but numerical-range prosecution history and prior-art arguments would be important. What formulations are protected by US 11,839,689?The strongest commercial read-through is to an immediate-release enzalutamide tablet using an HPMCAS-based spray-dried dispersion. The claims do not expressly require:
Those omissions broaden the composition claims but may create validity and enablement questions. The patent owner must show that the specification supports the full claim scope, including relevant HPMCAS grades, composition ranges, processing conditions, and stability outcomes. How strong is the patent estate for enzalutamide?US 11,839,689 is a formulation patent within a broader Xtandi patent estate. Enzalutamide is also protected by earlier patents directed to the active compound, androgen-receptor antagonism, synthesis, crystalline forms, formulations, and methods of treatment.
The 11,839,689 patent is more targeted than a compound patent. Its commercial strength is highest where the approved or proposed generic product uses the same HPMCAS spray-dried dispersion and 80-mg tablet design. Its strength is lower against a technically different formulation that uses another polymer or a different manufacturing process. When does enzalutamide lose exclusivity?Enzalutamide’s exclusivity is not determined by US 11,839,689 alone. A generic launch requires analysis of every blocking patent listed in the Orange Book, applicable regulatory exclusivity, litigation outcomes, and any settlement agreement. US 11,839,689 issued on December 12, 2023. Its nominal patent term is calculated from the applicable earliest nonprovisional or international filing date, subject to patent-term adjustment and any terminal disclaimer. The relevant expiration date must be taken from the USPTO Patent Center record and the patent’s official term data, not inferred from the issue date. [1] The patent should be separated from FDA exclusivity:
What is the Orange Book status of US 11,839,689?The FDA Orange Book is the controlling source for determining whether a patent is listed against Xtandi or an approved enzalutamide product. A patent can cover a marketed formulation without being listed. Conversely, an Orange Book listing does not prove that every generic formulation infringes. For a listed patent, an ANDA applicant generally must make one of four certifications:
A Paragraph IV notice letter can trigger Hatch-Waxman litigation. A timely suit by the patent owner generally creates a 30-month stay of final FDA approval, subject to statutory exceptions and court decisions. [2] The practical Orange Book question is whether US 11,839,689 is listed against the specific enzalutamide reference product and whether the listing covers the 40-mg and 80-mg tablets. The listing date, patent-use code, dosage-form scope, and any delisting should be checked in the FDA’s current electronic Orange Book. [3] Which companies are challenging enzalutamide patents?Generic competition to Xtandi is expected to come through ANDA applicants rather than biosimilar developers. Enzalutamide is a chemically synthesized small molecule, so the US pathway is an ANDA under section 505(j), not a biosimilar application under section 351(k). Public generic activity has historically involved multiple ANDA applicants seeking approval for enzalutamide capsules or tablets. The principal legal risk is not limited to the compound patent. Applicants may challenge formulation and method-of-use patents through Paragraph IV certifications or may pursue noninfringing products with Paragraph III certifications. A complete company-by-company challenge list must be tied to current FDA records and federal docket filings. Patent disputes can change through settlements, dismissals, covenant-not-to-sue agreements, or amended ANDA certifications. The core competitive categories are:
What patent litigation affects US 11,839,689?A patent number should not be treated as litigated merely because it is part of the Xtandi patent estate. The relevant litigation questions are:
For this patent, likely dispute areas include obviousness of amorphous enzalutamide-HPMCAS dispersions, anticipation by prior solid-dispersion references, written-description support for the full stability limitation, and enablement across HPMCAS grades and process conditions. A generic applicant could argue that HPMCAS was a known polymer for improving dissolution of poorly soluble compounds and that selecting it for enzalutamide was routine. The patent owner would likely rely on unexpected physical stability, dissolution, bioavailability, manufacturability, or tablet-performance results. What generic launch risks exist?Scenario 1: Early launch after a Paragraph IV settlementA settlement may permit launch before patent expiration, subject to a negotiated date, supply arrangement, or license. The commercial effect depends on whether multiple generic applicants receive similar dates. Scenario 2: Launch after a successful noninfringement defenseA generic using a different polymer or non-spray-drying process may avoid the formulation claims. The remaining risk would come from broader compound, method, solid-state, or manufacturing patents. Scenario 3: Launch after invalidationAn obviousness or anticipation judgment against the patent would remove the patent as a barrier, subject to appeal and other patents in the estate. Scenario 4: At-risk launchA generic may launch before final resolution after weighing damages, injunction risk, and the strength of the asserted claims. This scenario is more likely when multiple patents have expired or been narrowed. Scenario 5: Delayed approval based on Paragraph IIIAn applicant may accept the patent’s validity or avoid litigation by seeking approval after the listed patent expiration date. How does US 11,839,689 compare with compound and method-of-use patents?US 11,839,689 is narrower than a compound patent but can be commercially important because it targets the finished product. A compound patent usually blocks all products containing the claimed active ingredient, subject to claim scope and validity. A formulation patent blocks only products practicing the specified formulation features.
What manufacturing and IP barriers does the patent create?The patent can increase development costs even if a competitor ultimately designs around it. A generic developer may need to:
The patent does not by itself prevent a competitor from manufacturing enzalutamide. It creates a risk around a particular formulation architecture and may require a technically distinct product. What is the revenue exposure?Xtandi is a major oncology product marketed by Astellas and Pfizer. Revenue exposure to this patent depends on the proportion of US sales attributable to tablets that practice claims 4 through 7, the timing of generic entry, the number of entrants, and price erosion after launch. The 80-mg claim is commercially significant because the approved Xtandi tablet is available in an 80-mg strength. The 40-mg strength remains relevant to the broader tablet claims and to product-switching strategies. A formulation patent can preserve branded share even after an active-ingredient patent expires if generic applicants cannot use the same dosage form without litigation risk. Revenue modeling should use a scenario range based on:
Key Takeaways
FAQs About US Patent 11,839,689Does US 11,839,689 cover Xtandi?It may cover Xtandi tablets if the marketed product contains the claimed amorphous enzalutamide-HPMCAS solid dispersion and satisfies the relevant tablet and excipient limitations. Coverage must be determined through product composition evidence and claim construction. Can a generic enzalutamide product avoid US 11,839,689?A generic may seek to avoid infringement by using a different polymer, a non-spray-drying process, a different physical form, or tablet excipient levels outside the claimed ranges. The product would still need to clear other enzalutamide patents. Is US 11,839,689 a biosimilar patent?No. Enzalutamide is a chemically synthesized small molecule. Generic applicants use the ANDA pathway rather than the FDA biosimilar pathway. Does the 80-mg limitation apply to all claims?No. The 80-mg limitation appears in claim 5. Claim 1 does not require an 80-mg dose, and claim 7 does not expressly require 80 mg unless it depends on or is interpreted with a claim containing that limitation. What is the main validity vulnerability?The principal potential defenses are obviousness based on known amorphous solid-dispersion technology, anticipation by prior art, insufficient written-description support for the full claim scope, and inadequate enablement of the stability limitation. References
More… ↓ |
Drugs Protected by US Patent 11,839,689
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Astellas | XTANDI | enzalutamide | TABLET;ORAL | 213674-001 | Aug 4, 2020 | AB | RX | Yes | No | 11,839,689 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Astellas | XTANDI | enzalutamide | TABLET;ORAL | 213674-002 | Aug 4, 2020 | AB | RX | Yes | Yes | 11,839,689 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,839,689
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2013315619 | ⤷ Start Trial | |||
| Australia | 2018200316 | ⤷ Start Trial | |||
| Brazil | 112015005432 | ⤷ Start Trial | |||
| Canada | 2884795 | ⤷ Start Trial | |||
| China | 105358535 | ⤷ Start Trial | |||
| China | 109897004 | ⤷ Start Trial | |||
| Cyprus | 1124729 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
